Adjuvant Therapy in Pancreatic Ductal Adenocarcinoma—Past, Present, and Future
Andy Tran, Tejeshwar Jain, Naomi Fei, Vikas Dudeja · 2026
Read Adjuvant Therapy in Pancreatic Ductal Adenocarcinoma—Past, Present, and Future by Andy Tran, Tejeshwar Jain, Naomi Fei, Vikas Dudeja (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13565269.txt.
Description
Andy Tran and three co-authors review extra treatment after pancreatic cancer surgery in this two thousand twenty-six paper. Pancreatic ductal adenocarcinoma is among the deadliest cancers. Surgery offers the only chance of cure, yet the cancer often returns. Adjuvant therapy, given after surgery, aims to kill what remains. Over two decades, trials moved care from single drugs to multi-drug regimens.
Chemotherapy after surgery is now a firm standard. Radiation paired with chemotherapy stays debated, with trials split on its value. Newer options include targeted drugs, biomarker-guided choices, and immune therapies for select patients. The review walks through the landmark trials behind each shift. It closes with what ongoing trials may settle. Oncologists who treat this cancer are the readers.
Catalog record
| CREATOR | Andy Tran, Tejeshwar Jain, Naomi Fei, Vikas Dudeja |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |